Por favor, use este identificador para citar o enlazar este ítem:
https://repositorio.ufba.br/handle/ri/5447
metadata.dc.type: | Artigo de Periódico |
Título : | Lack of association of indoleamine 2,3-dioxygenase polymorphisms with interferon-alpha-related depression in hepatitis C |
Otros títulos : | Brain, Behavior, and Immunity |
Autor : | Almeida, Amanda Cristina Galvão Oliveira de Quarantini, Lucas de Castro Sampaio, Aline Santos Lyra, André Castro Parise, Carmen Lívia Paraná, Raymundo Oliveira, Irismar Reis de Koenen, Karestan C. Scippa, Ângela Marisa de Aquino Miranda Guindalini, Camila |
metadata.dc.creator: | Almeida, Amanda Cristina Galvão Oliveira de Quarantini, Lucas de Castro Sampaio, Aline Santos Lyra, André Castro Parise, Carmen Lívia Paraná, Raymundo Oliveira, Irismar Reis de Koenen, Karestan C. Scippa, Ângela Marisa de Aquino Miranda Guindalini, Camila |
Resumen : | Background: Major depression is a frequent adverse effect of interferon-alpha (IFN-a) therapy. Although the indoleamine 2,3-dioxygenase (IDO) enzyme seems to be involved in the pathophysiology of IFN-a-induced depression, no pharmacogenetic study has investigated whether variation in the IDO gene mod-ifies vulnerability to this adverse effect. Methods: A cross-sectional study assessing 277 hepatitis C patients recruited in two specialized outpa-tient clinics of Brazil. They were interviewed with the Mini International Neuropsychiatric Interview (MINI) approximately 1 month after the end of IFN-a plus ribavirin therapy. Genomic DNA of individuals was extracted from venous blood. Three IDO single-nucleotide polymorphisms (SNPs) were genotyped (rs3824259; rs10089084 and rs35099072).Results: MINI indicated that 21.3% of the sample met criteria for a major depressive episode during the course of IFN-a therapy. No association with the diagnosis of a major depressive episode during the course of IFN-a therapy was observed genotype or allele-wise (p > 0.05). Current major depression and/or current anxiety disorder was significantly associated with IFN-a-related depression (p < 0.005). However, gender, age, route of infection, result of the antiviral treatment, past history of substance use disorders, depression or any other psychiatric disorder showed no association with IFN-a-related depression (p > 0.05). Conclusions: Our results suggest no influence of the variants in the IDO gene and the diagnosis of inter- feron-a-related depression in the Brazilian population. Interferon-a-related depression may impose per-sistent psychopathology on at least 15% of the depressed patients even 2 years after antiviral therapy termination. The cross-sectional design is a limitation of our study, predisposing memory bias. Prospec- tive pharmacogenetic studies are warranted to continue investigation of the impact of IDO polymorphisms on the development of IFN-a-induced depression. |
Palabras clave : | Genetic polymorphism Major depressive disorder Hepatitis C Interferon-alpha Pharmacogenetics Substance-related disorders |
URI : | http://www.repositorio.ufba.br/ri/handle/ri/5447 |
Fecha de publicación : | 2011 |
Aparece en las colecciones: | Artigo Publicado em Periódico (Faculdade de Medicina) |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
nps67.tmp.pdf Restricted Access | 106,81 kB | Adobe PDF | Visualizar/Abrir Request a copy |
Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.